thalidomide has been researched along with Kidney Failure, Chronic in 25 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our observation that thalidomide administration to a dialysis patient with leprosy alleviated his pruritus led us to conduct this short-term study to assess the efficacy of the drug in this regard." | 9.07 | Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. ( Hoette, M; Lugon, JR; Lugon, NV; Ruzany, F; Silva, SR; Viana, PC, 1994) |
| " A set of blood samples was taken in order to develop a pharmacokinetic model accounting for lenalidomide concentrations in this setting." | 5.46 | Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. ( Buclin, T; Burnier, M; Dao, K; Figg, WD; Kissling, S; Lu, Y; Peer, CJ; Stadelmann, R, 2017) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 5.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| "The pregnancy was complicated by dialysis difficulties, uncontrollable hypertension and deteriorating renal function resulting in fetal loss at 26-weeks' gestation." | 5.28 | Thalidomide, pregnancy and renal failure. ( Brown, MA; Child, RP; Farrell, C; Newton, P, 1990) |
| "The impact of high dose dexamethasone containing regimens with or without the novel agents thalidomide and bortezomib on the reversal of renal failure (RF) was evaluated in 41 consecutive newly diagnosed patients with multiple myeloma (MM) treated in a single institution." | 5.12 | Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. ( Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M, 2007) |
| "Our observation that thalidomide administration to a dialysis patient with leprosy alleviated his pruritus led us to conduct this short-term study to assess the efficacy of the drug in this regard." | 5.07 | Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. ( Hoette, M; Lugon, JR; Lugon, NV; Ruzany, F; Silva, SR; Viana, PC, 1994) |
| " The differences in pharmacokinetic parameters between normal renal function and mild renal impairment were minor to modest (11%-32%)." | 2.73 | Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. ( Chen, N; Knight, R; Kong, L; Kumar, G; Laskin, OL; Lau, H; Zeldis, JB, 2007) |
| "Thalidomide concentration was determined by HPLC." | 2.71 | Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. ( Don, BR; Eriksson, T; Höglund, P; Kaysen, GA; Scheffler, M; Turesson, I; Vu, J; Waage, A, 2003) |
| "The treatment of multiple myeloma (MM) has undergone significant developments in recent years." | 2.46 | Current multiple myeloma treatment strategies with novel agents: a European perspective. ( Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S, 2010) |
| " A set of blood samples was taken in order to develop a pharmacokinetic model accounting for lenalidomide concentrations in this setting." | 1.46 | Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. ( Buclin, T; Burnier, M; Dao, K; Figg, WD; Kissling, S; Lu, Y; Peer, CJ; Stadelmann, R, 2017) |
| "Multiple myeloma is a clonal B-cell malignancy, characterised by proliferation of plasma cells and secretion of paraproteins." | 1.43 | Pleural effusion as a manifestation of multiple myeloma. ( Iqbal, N; Majid, H; Shaikh, MU; Tariq, MU, 2016) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 1.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| "Zoledronic acid was given to both patients by 15 minutes intravenous infusion followed by hemodialysis 24 hours later." | 1.35 | [Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases]. ( Arima, S; Hayakawa, K; Hoshinaga, K; Kusaka, M; Maruyama, T; Miyakawa, S; Mori, S; Sasaki, H; Shiroki, R, 2008) |
| "The pregnancy was complicated by dialysis difficulties, uncontrollable hypertension and deteriorating renal function resulting in fetal loss at 26-weeks' gestation." | 1.28 | Thalidomide, pregnancy and renal failure. ( Brown, MA; Child, RP; Farrell, C; Newton, P, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mesa-Gutiérrez, JC | 1 |
| Rouras-López, A | 1 |
| Amías-Lamana, V | 1 |
| Hoyos-Chacón, J | 1 |
| Cabiró-Badimón, I | 1 |
| Porta-Monnet, J | 1 |
| Tan, J | 1 |
| Lam-Po-Tang, M | 1 |
| Hutchison, CA | 1 |
| de Zoysa, JR | 1 |
| Gkotzamanidou, M | 1 |
| Terpos, E | 1 |
| Kastritis, E | 2 |
| Dimopoulos, MA | 2 |
| Iqbal, N | 1 |
| Tariq, MU | 1 |
| Shaikh, MU | 1 |
| Majid, H | 1 |
| Dao, K | 1 |
| Lu, Y | 1 |
| Peer, CJ | 1 |
| Figg, WD | 1 |
| Stadelmann, R | 1 |
| Burnier, M | 1 |
| Buclin, T | 1 |
| Kissling, S | 1 |
| Arima, S | 1 |
| Shiroki, R | 1 |
| Mori, S | 1 |
| Maruyama, T | 1 |
| Sasaki, H | 1 |
| Kusaka, M | 1 |
| Miyakawa, S | 1 |
| Hayakawa, K | 1 |
| Hoshinaga, K | 1 |
| Mimidis, K | 1 |
| Kaliontzidou, M | 1 |
| Tzimas, T | 1 |
| Papadopoulos, V | 1 |
| Pandit, A | 1 |
| Gangurde, S | 1 |
| Gupta, SB | 1 |
| Ludwig, H | 1 |
| Beksac, M | 1 |
| Bladé, J | 1 |
| Boccadoro, M | 1 |
| Cavenagh, J | 1 |
| Cavo, M | 1 |
| Dimopoulos, M | 1 |
| Drach, J | 1 |
| Einsele, H | 1 |
| Facon, T | 1 |
| Goldschmidt, H | 1 |
| Harousseau, JL | 1 |
| Hess, U | 1 |
| Ketterer, N | 1 |
| Kropff, M | 1 |
| Mendeleeva, L | 1 |
| Morgan, G | 1 |
| Palumbo, A | 1 |
| Plesner, T | 1 |
| San Miguel, J | 1 |
| Shpilberg, O | 1 |
| Sondergeld, P | 1 |
| Sonneveld, P | 1 |
| Zweegman, S | 1 |
| Pinto, V | 1 |
| Castelli, A | 1 |
| Gaidano, G | 1 |
| Conconi, A | 1 |
| Berk, DR | 1 |
| Miller, A | 1 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
| Desport, E | 2 |
| Moumas, E | 2 |
| Abraham, J | 2 |
| Delbès, S | 2 |
| Lacotte-Thierry, L | 2 |
| Touchard, G | 2 |
| Fermand, JP | 2 |
| Bridoux, F | 2 |
| Jaccard, A | 2 |
| Hanf, W | 1 |
| Debiais, C | 1 |
| Ramasamy, K | 1 |
| Hazel, B | 1 |
| Mahmood, S | 1 |
| Corderoy, S | 1 |
| Schey, S | 1 |
| Kleber, M | 1 |
| Ihorst, G | 1 |
| Udi, J | 1 |
| Koch, B | 1 |
| Wäsch, R | 1 |
| Engelhardt, M | 1 |
| Dan, K | 1 |
| Hayashi, T | 1 |
| Yamaguchi, I | 1 |
| Saitoh, H | 1 |
| Takagi, M | 1 |
| Nonaka, Y | 1 |
| Nomura, T | 1 |
| Gibbs, PJ | 1 |
| Friend, PJ | 1 |
| Darby, CR | 1 |
| Eriksson, T | 1 |
| Höglund, P | 1 |
| Turesson, I | 1 |
| Waage, A | 1 |
| Don, BR | 1 |
| Vu, J | 1 |
| Scheffler, M | 1 |
| Kaysen, GA | 1 |
| Fakhouri, F | 1 |
| Guerraoui, H | 1 |
| Presne, C | 1 |
| Peltier, J | 1 |
| Delarue, R | 1 |
| Muret, P | 1 |
| Knebelmann, B | 1 |
| Anagnostopoulos, A | 1 |
| Roussou, M | 1 |
| Gika, D | 1 |
| Matsouka, C | 1 |
| Barmparousi, D | 1 |
| Grapsa, I | 1 |
| Psimenou, E | 1 |
| Bamias, A | 1 |
| Chen, N | 1 |
| Lau, H | 1 |
| Kong, L | 1 |
| Kumar, G | 1 |
| Zeldis, JB | 1 |
| Knight, R | 1 |
| Laskin, OL | 1 |
| Silva, SR | 1 |
| Viana, PC | 1 |
| Lugon, NV | 1 |
| Hoette, M | 1 |
| Ruzany, F | 1 |
| Lugon, JR | 1 |
| Bielsa, I | 1 |
| Teixidó, J | 1 |
| Ribera, M | 1 |
| Ferrándiz, C | 1 |
| Brown, MA | 1 |
| Farrell, C | 1 |
| Newton, P | 1 |
| Child, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min[NCT02424851] | Phase 2 | 31 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02424851)
Timeframe: End of week 6 (after receiving two cycles of therapy)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 13 |
| Arm B (BTD) | 3 |
(NCT02424851)
Timeframe: 1 month post end of treatment and 1 year post randomisation
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 9 |
| Arm B (BTD) | 13 |
(NCT02424851)
Timeframe: End of weeks 3, 6, 9, 12 (after receiving 4 cycles of therapy), 30 days after final treatment and 12 months after randomisation
| Intervention | Events (Number) | |
|---|---|---|
| Serious adverse events | Adverse events | |
| Arm A (BBD) | 2 | 3 |
| Arm B (BTD) | 0 | 6 |
"The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is scored on a scale of 1 to 3: 1 (no problems), 2 (some problems), and 3 (extreme problems). Higher score equates to a worse outcome.~As stated in the official EQ-5D user guide, patient responses to the 5 questions were converted into a single index value as per Dolan P (1997). Modeling valuations for EuroQol health states. Med Care 35(11):1095-108. These index values, with country specific value sets, facilitate the calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions. In the UK, the values range from -0.594 to +1." (NCT02424851)
Timeframe: Baseline and 1 month follow up
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month FU | |
| Arm A (BBD) | 0.72 | 0.69 |
| Arm B (BTD) | 0.69 | 0.80 |
(NCT02424851)
Timeframe: End of 2nd treatment cycle, week 6
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Partial response | Minor response | No repsonse | |
| Arm A (BBD) | 2 | 9 | 4 |
| Arm B (BTD) | 0 | 7 | 6 |
3 reviews available for thalidomide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Ch | 2010 |
[Current treatment of AL amyloidosis].
Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development | 2011 |
[New insights in the treatment of myeloma with renal failure].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2011 |
5 trials available for thalidomide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethaso | 2011 |
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
Topics: Adult; Aged; Confidence Intervals; Female; Humans; Immunosuppressive Agents; Kidney Failure, Chronic | 2003 |
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; | 2007 |
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Disease Progression; Dos | 2007 |
Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial.
Topics: Aged; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Kidney Failure, Chronic; Mal | 1994 |
17 other studies available for thalidomide and Kidney Failure, Chronic
| Article | Year |
|---|---|
[Crystalline keratopathy due to kappa chains in a monoclonal gammopathy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Corn | 2013 |
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethas | 2014 |
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Fatig | 2014 |
Pleural effusion as a manifestation of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diagnosis, Differen | 2016 |
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myelo | 2017 |
[Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Carcinoma, Renal Cell; Chronic Dise | 2008 |
Thalidomide for treatment of bleeding angiodysplasias during hemodialysis.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Kidney Failure, | 2008 |
Autonomic failure in primary amyloidosis.
Topics: Amyloidosis; Diagnosis, Differential; Humans; Hypotension, Orthostatic; Kidney Failure, Chronic; Mal | 2008 |
Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Combined Modality Therapy; Cyclams; De | 2010 |
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Dep | 2012 |
Thalidomide as a targeted therapy for multiple myeloma.
Topics: Angiogenesis Inhibitors; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Multiple Myeloma | 2003 |
Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis.
Topics: Humans; Immunoglobulin D; Immunosuppressive Agents; Kidney Failure, Chronic; Male; Middle Aged; Mult | 2003 |
Renal replacement therapy in a patient with phocomelia.
Topics: Adult; Ectromelia; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; Polycystic Kidne | 2003 |
Thalidomide in patients with multiple myeloma and renal failure.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Hyperkalemia; Kidney Failure, Chronic; Male; Middle A | 2004 |
Erythroderma due to thalidomide: report of two cases.
Topics: Adult; Dermatitis, Exfoliative; Drug Eruptions; Eosinophilia; Female; Humans; Kidney Failure, Chroni | 1994 |
Thalidomide, pregnancy and renal failure.
Topics: Adult; Antihypertensive Agents; Combined Modality Therapy; Female; Humans; Hypertension; Kidney Fail | 1990 |